# Angiodynamics Inc: Form 10-Q for the period ended Feb 28, 2018

- Company: [Angiodynamics Inc](/companies/ango.md) (CIK 1275187)
- Form: 10-Q
- Filed: 2018-04-05
- Accepted by EDGAR: Apr 5, 2018, 10:19 ET
- Period: 2018-02-28
- Accession: 0001275187-18-000007
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1275187/000127518718000007/ango-22818x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1275187/000127518718000007/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-02-28.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Gross profit | 3 months, 2017-12-01 to 2018-02-28 | $45.4m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2017-06-01 to 2018-02-28 | $129.4m | us-gaap:GrossProfit |
| Research and development | 3 months, 2017-12-01 to 2018-02-28 | $6.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2017-06-01 to 2018-02-28 | $19.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2017-12-01 to 2018-02-28 | $4.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2017-06-01 to 2018-02-28 | $6.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2017-12-01 to 2018-02-28 | $740.0k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2017-06-01 to 2018-02-28 | $2.2m | us-gaap:InterestExpense |
| Income tax | 3 months, 2017-12-01 to 2018-02-28 | −$9.9m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2017-06-01 to 2018-02-28 | −$10.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2017-12-01 to 2018-02-28 | $14.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2017-06-01 to 2018-02-28 | $14.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-12-01 to 2018-02-28 | $0.37 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2017-06-01 to 2018-02-28 | $0.38 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2017-12-01 to 2018-02-28 | $0.38 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2017-06-01 to 2018-02-28 | $0.38 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2017-12-01 to 2018-02-28 | 37,442,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2017-06-01 to 2018-02-28 | 37,358,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2017-06-01 to 2018-02-28 | $17.5m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 9 months, 2017-06-01 to 2018-02-28 | $1.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months, 2017-06-01 to 2018-02-28 | $0 | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2018-02-28 | $52.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-02-28 | $156.6m | us-gaap:AssetsCurrent |
| Total assets | at 2018-02-28 | $698.4m | us-gaap:Assets |
| Current liabilities | at 2018-02-28 | $54.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2018-02-28 | $160.1m | us-gaap:Liabilities |
| Long-term debt | at 2018-02-28 | $87.8m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2018-02-28 | $5.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2018-02-28 | $538.3m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 42,412 characters.

The following information should be read together with the consolidated financial statements and the notes thereto and other information included elsewhere in this quarterly report on Form 10-Q.

### Forward-Looking Statements

This quarterly report on Form 10-Q, including the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from our expectations. Factors that may affect our actual results achieved include, without limitation, our ability to develop existing and new products, future actions by FDA or other regulatory agencies, results of pending or future clinical trials, the results of ongoing litigation, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as our ability to integrate purchased businesses. Other risks and uncertainties include, but are not limited to, the factors described from time to time in our reports filed with the SEC.

Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this quarterly report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. AngioDynamics disclaims any obligation to update the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this document.

### EXECUTIVE OVERVIEW

### Company and Market

We design, manufacture and sell a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Our devices are generally used in minimally invasive, image-guided procedures. Most of our products are intended to be used once and then discarded, or they may be temporarily implanted for short- or longer-term use.

Our business operations cross a variety of markets. Our financial performance is impacted by changing market dynamics, which have included an emergence of value-based purchasing by healthcare providers, consolidation of healthcare providers, the increased role of the consumer in health care decision-making and an aging population, among others. In addition, our growth is impacted by changes within our sector, such as the merging of competitors to gain scale and influence, changes in the regulatory environment for medical devices and fluctuations in the global economy.

Our sales and profitability growth also depends, in part, on the introduction of new and innovative products, together with ongoing enhancements to our existing products. Expansions to our product offerings are created through internal product development, technology licensing and strategic alliances. We recognize the importance of, and intend to continue to make investments in, research and development activities and business development opportunities. We feel confident that our existing capital structure and free cash flow generation will allow us to properly fund those activities.

We sell our products in the United States primarily through a direct sales force, and outside the U.S. through a combination of a direct sales and distributor relationships. We expect our businesses to grow in both sales and profitability through geographic expansion, market penetration, new product introductions and increasing our direct presence internationally.

In evaluating the operating performance of our business, management focuses on revenue, gross margin, operating income, earnings per share and cash flow from operations. A summary of these key financial metrics for the three and nine months ended February 28, 2018 compared to the three and nine months ended February 28, 2017 follows:

Three months ended February 28, 2018:

- Revenue decreased by 2.0% to $83.9 million
- Gross margin as a percentage of sales increased by 300 bps to 54.2%
- Operating income decreased by $0.3 million to $4.9 million
- Earnings per share increased by $0.30 to $0.38

Nine months ended February 28, 2018:

- Revenue decreased by 2.6% to $256.0 million
- Gross margin as a percentage of sales decreased by 0.3% to 50.6%
- Operating income decreased by $18.2 million to $6.1 million
- Earnings per share decreased by $0.11 to $0.38
- Cash flow from operations decreased by $19.2 million to $17.5 million

The decline in revenue during the third quarter was primarily driven by declines in the Venous portfolio within Peripheral Vascular, non-BioFlo products within Vascular Access and Radiofrequency Ablation within Oncology/Surgery. The decrease in Radiofrequency Ablation was primarily due to the discontinuation of this product line in Japan. In the prior year there was a $1.7 million sale to introduce Radiofrequency Ablation into the Japanese market.

The decline was partially offset by increased sales of Solero, a microwave ablation device that received FDA clearance during the first quarter of fiscal year 2018, and NanoKnife capital sales in Oncology/Surgery. Other areas of growth include Fluid Management, AngioVac and Core within Peripheral Vascular and the BioFlo family of products within Vascular Access.

### New Accounting Pronouncements

Information regarding new accounting pronouncements is included in Note 15 to our consolidated financial statements in this Quarterly Report on Form 10-Q.

### Results of Operations for the Three Months ended February 28, 2018 and 2017

For the three months ended February 28, 2018, we reported net income of $14.0 million, or $0.37per diluted share, on net sales of $83.9 million, compared with net income of $2.9 million, or $0.08 per share, on net sales of $85.6 million during the same quarter of the prior year.

### Net Sales

Net sales - Net sales are derived from the sale of our products and related freight charges, less discounts and returns.

Net sales for the three months ended February 28, 2018 and 2017:

| Net Sales by Product Category | Three months ended Feb 28, 2018 | Feb 28, 2017 | % Growth |
| --- | ---: | ---: | ---: |
| Peripheral Vascular | $48,517 | $48,929 | (1)% |
| Vascular Access | 23,279 | 23,680 | (2)% |
| Oncology/Surgery | 12,055 | 12,993 | (7)% |
| Total | $83,851 | $85,602 | (2)% |
| Net Sales by Geography |  |  |  |
| United States | $65,787 | $67,656 | (3)% |
| International | 18,064 | 17,946 | 1% |
| Total | $83,851 | $85,602 | (2)% |

For the three months ended February 28, 2018, net sales decreased $1.8 million to $83.9 million compared to the same period in the prior year.

- Consolidated and U.S. net sales decreased from the prior year as a result of lower net sales across all Global Business Units.

#### Peripheral Vascular

- Total Peripheral Vascular sales decreased $0.4 million primarily attributable to decreased sales volume of Venous products of $2.7 million due to reimbursement challenges. This decrease was offset by strong performance in our Fluid Management and core product lines, which increased $1.2 million and $0.7 million, respectively. The increase in Fluid Management was attributed to the Fluid Management dedicated sales team being fully staffed and promoting new custom kits.
- U.S. Peripheral Vascular sales decreased $1.2 million due to decreased sales volume of Venous products. This decreased sales volume in the U.S. was offset by an increase in volume in Fluid Management and Thrombus Management categories. International Peripheral Vascular sales increased $0.8 million due to increased sales volume in Fluid Management.

#### Vascular Access

- Total Vascular Access sales decreased $0.4 million primarily in our non-BioFlo businesses. Our BioFlo product lines, other than BioFlo PICCs, increased $0.8 million year over year. This was offset by decreased sales of BioFlo PICCs of $1.1 million. BioFlo product lines comprise 48% of our overall vascular access sales, compared to 49% a year ago.
- U.S. Vascular Access sales declined by 3% due to softness across the non-BioFlo portfolio. This was partially offset by growth in Midline and BioFlo Dialysis products which continue to gain traction in the marketplace.
- International Vascular Access sales increased by $0.1 million.

#### Oncology/Surgery

- Total Oncology/Surgery sales decreased $0.9 million year over year primarily due to decreased sales in Radiofrequency Ablation and NanoKnife disposables. The decrease in Radiofrequency Ablation was primarily due to the discontinuation of this product line in Japan. In the prior year there was a $1.7 million sale to introduce Radiofrequency Ablation into the Japanese market. This was partially offset by the successful launch of our Solero product line, which generated $0.5 million of growth year over year, and increased sales of NanoKnife generators.
- U.S. Oncology/Surgery decreased by 2%, driven by decreased sales in Radiofrequency Ablation and NanoKnife disposables partially offset by increased sales in NanoKnife generators of $0.5 million.
- International Oncology/Surgery sales decreased by $0.9 million year over year as a result of decreased Radiofrequency sales of $1.9 million offset by Solero Microwave capital and disposable sales growth of $0.5 million and NanoKnife generators sales growth of $0.6 million.

### Gross Profit, Operating expenses, and Other income (expense)

|  | Three months ended Feb 28, 2018 | Feb 28, 2017 | % Change |
| --- | ---: | ---: | ---: |
| Gross profit | $45.4 | $43.8 | 4% |
| Gross profit % of sales | 54.2% | 51.2% |  |
| Research and development | $6.5 | $6.0 | 8% |
| % of sales | 7.7% | 7.0% |  |
| Selling and marketing | $18.0 | $19.4 | (7)% |
| % of sales | 21.5% | 22.7% |  |
| General and administrative | $7.7 | $7.1 | 8% |
| % of sales | 9.2% | 8.2% |  |

Gross profit - Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead, exclusive of intangible amortization.

Gross profit increased by $1.6 million compared to the prior year. The increase is attributable to the following:

- Net productivity of approximately $1.8 million, the expiration of a royalty agreement in September of approximately $1.5 million and currency of $0.6 million. These increases were partially offset by volume, mix and freight of approximately $2.4 million.

Research and development expenses - Research and development (“R&D”) expenses include internal and external costs to develop new products, enhance existing products, validate new and enhanced products, and manage clinical, regulatory and medical affairs.

R&D expense increased $0.5 million compared to the prior year. The increase is attributable to the following:

- Timing of project spend in the third quarter of fiscal year 2018 compared to prior year was up $0.1 million along with increased compensation and benefits associated with additional headcount of $0.4 million.

Sales and marketing expenses - Sales and marketing (“S&M”) expenses consist primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities.

S&M expense decreased by $1.4 million compared to the prior year. The decrease is attributable to the following:

- Compensation and benefits decrease of approximately $1.8 million, which was primarily the result of decreased variable compensation of $0.7 million and open headcount of $0.5 million. In addition, severance expense was down $0.6 million from the third quarter of the prior year.
- Open headcount resulted in increased travel of $0.2 million and recruiting expense of $0.2 million.
- Lower consulting spend of $0.2 million.

General and administrative expenses - General and administrative (“G&A”) expenses include executive management, finance, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities.

G&A expense increased by $0.6 million compared to the prior year. The increase is attributable to the following:

- Compensation and benefits increase of approximately $1.4 million was primarily the result of increased headcount year over year of $0.4 million and increased benefits expense of $0.9 million.
- The increase in compensation and benefits was partially offset by lower depreciation of $0.2 million, a decrease in bad debt expense of $0.2 million, a decrease in recruiting expense of $0.2 million and a decrease in travel expense of $0.1 million.

|  | Three months ended Feb 28, 2018 | Feb 28, 2017 | $ Change |
| --- | ---: | ---: | ---: |
| Amortization of intangibles | $4.2 | $4.4 | $(0.2) |
| Change in fair value of contingent consideration | $— | $0.1 | $(0.1) |
| Acquisition, restructuring and other items, net | $4.2 | $1.8 | $2.4 |
| Other expense | $(0.8) | $(0.6) | $(0.2) |

Amortization of intangibles - Represents the amount of amortization expense that was taken on intangibles assets held by the Company.

- The decrease of $0.2 million is primarily related to intangible assets that became fully amortized during the prior year.

Change in fair value of contingent consideration - Represents changes in contingent consideration driven by changes to estimated future payments on earn-out liabilities created through acquisitions and amortization of present value discounts on long-term contingent consideration.

- The decrease is due to the fact that in the second quarter of fiscal year 2018, the final minimum payment was made on the AngioVac product contingent consideration. The normal amortization of the present value discount on the contingent liabilities is now less than $0.1 million per quarter.

Acquisition, restructuring and other items, net - Represents costs associated with mergers and acquisitions, restructuring expenses, legal costs that are related to litigation that is not in the ordinary course of business, legal settlements and other one-time items.

Acquisition, restructuring and other items, net increased by $2.4 million compared to the prior year. The increase is attributable to the following:

- There was $1.5 million of expense related to the plant consolidation that was announced in the third quarter of fiscal year 2017. The expense consisted mainly of severance of $0.3 million and costs to move the product lines including equipment transfer expenses, accelerated depreciation for assets that will not be transferred, validation of products and other start up costs of $1.2 million. This is compared to $0.2 million of severance in the prior year.
- Legal expenses, related to litigation that is outside of the normal course of business, of $2.3 million were recorded in the current year compared to $1.5 million in the prior year.

Other expenses - Other expenses include interest expense, foreign currency impacts, bank fees, and amortization of deferred financing costs.

- The increase in other expenses from the prior year is due to the increased interest expense of $0.2 million.

### Income Tax Provision (Benefit)

|  | Three months ended Feb 28, 2018 | Feb 28, 2017 |
| --- | ---: | ---: |
| Income tax expense (benefit) | $(9.9) | $1.7 |
| Effective tax rate including discrete items | (244.4)% | 36.6% |

Our effective tax rate including discrete items for the three month periods ended February 28, 2018 and 2017 was (244.4)% and 36.6%, respectively.

The estimated annual effective tax rate, however, prior to discrete items was 4.9% in the third quarter of fiscal 2018, as compared to 42.9% for the same period in fiscal 2017. The Company’s effective tax rate differs from the U.S. statutory rate primarily due to the valuation allowance, foreign taxes and state taxes. The change from the prior quarter fiscal year 2017 is principally related to the enactment of the Tax Cuts and Jobs Act (“Tax Reform Act”) as it relates to amortization of goodwill for tax purposes which will no longer be treated as a permanent item in our tax provision.

On December 22, 2017, the President of the United States signed into law the Tax Reform Act. The legislation significantly changes U.S. tax law by, among other things, lowering corporate income tax rates, implementing a territorial tax system, expanding the tax base and imposing a tax deemed repatriated earnings of foreign subsidiaries. The Tax Reform Act permanently reduces the U.S. corporate federal income tax rate from a maximum of 35% to a flat 21% rate, effective January 1, 2018. The Company has recognized the impact of the Tax Reform Act in these unaudited consolidated financial statements and related disclosures. Staff Accounting Bulletin No. 118 (“SAB 118”) provides Companies with guidance on accounting for the impact of the Tax Reform Act. Specifically, SAB 118 provides for a measurement period, not to exceed one year, that begins on the date of enactment of December 22, 2017, and ends when the Company has obtained, prepared, and analyzed information needed to complete accounting requirements. In accordance with SAB 118, the Company recorded provisional amounts reflecting the impact of the Tax Reform Act in these unaudited consolidated financial statements and related disclosures.

As a result of the Tax Reform Act, in the third quarter of fiscal 2018, the Company has recognized a discrete tax benefit in the amount of $9.3 million due to the revaluation of the Company's indefinite lived deferred tax liability related to amortizable goodwill to reflect the lower statutory rate. Because the remaining U.S. deferred tax assets are offset by a full valuation allowance, the reduction in net deferred tax assets for the lower rate was fully offset by a corresponding reduction in valuation allowance resulting in no additional tax provision. The Tax Reform Act changed the NOL carryover rules and created a new limitation on their use. NOLs created in fiscal 2018 and beyond may be carried forwarded indefinitely but are limited to 80% of taxable income in any year. As a result of this change, the Company believes it is appropriate to offset some of its indefinite lived deferred tax liability against its deferred tax assets, and as a result, recognized an estimated $0.8 million discrete benefit in the third quarter of fiscal 2018. Additionally, this change impacts the Company's effective tax calculation on a go forward basis as the amortization of goodwill for tax purposes will no longer be treated as a permanent item in our tax provision.

The Tax Reform Act imposes a one-time transition tax on the deemed repatriation of post-1986 undistributed foreign subsidiaries’ earnings. Based on the information available as of December 31, 2017, the Company estimated undistributed foreign earnings of approximately $4.8 million. The taxable income arising from this deemed repatriation is expected to result in the utilization of net operating loss carryforwards and other tax credits, offset by changes in the valuation allowance, resulting in no net impact to tax expense. In accordance with SAB 118, the estimated income tax impact associated with the one-time transition tax of zero represents our best estimate based on interpretation of the U.S. legislation as we are still accumulating data to finalize the underlying calculation. In accordance with SAB 118, estimated income tax impact associated with the one-time transition tax is considered provisional and will be finalized prior to the end of the measurement period. The ultimate impact may differ from these provisional amounts, due to, among other things, additional analysis, changes in interpretations and assumptions the Company has made, additional regulatory guidance that may be issued, and actions the Company may take as a result of the Tax Reform Act.

A valuation allowance is established if it is more likely than not that all, or a portion of the deferred tax asset will not be realized. The Company has established that it is more likely than not that some, or all of their deferred tax assets will not be recognized in future years. Consequently, the Company continues to maintain a full U.S. valuation allowance on its net deferred tax assets. Management will continue to reevaluate the positive and negative evidence at each reporting period and if future results as projected in the U.S. and our tax planning strategies are favorable, the valuation allowance may be removed, which could have a favorable material impact on our results of operations in the period in which it is recorded.

### Results of Operations for the Nine Months ended February 28, 2018 and 2017

For the nine months ended February 28, 2018, we reported a net income of $14.2 million, or $0.38 per diluted share, on net sales of $256.0 million, compared with net income of $17.9 million, or $0.49 per share, on net sales of $262.7 million during the same quarter of the prior year.

### Net Sales

Net sales - Net sales are derived from the sale of our products and related freight charges, less discounts and returns.

Net sales for the nine months ended February 28, 2018 and 2017:

| Net Sales by Product Category | Nine months ended Feb 28, 2018 | Feb 28, 2017 | % Growth |
| --- | ---: | ---: | ---: |
| Peripheral Vascular | $149,751 | $154,654 | (3)% |
| Vascular Access | 69,091 | 72,238 | (4)% |
| Oncology/Surgery | 37,126 | 35,837 | 4% |
| Total | $255,968 | $262,729 | (3)% |
| Net Sales by Geography |  |  |  |
| United States | $203,020 | $211,295 | (4)% |
| International | 52,948 | 51,434 | 3% |
| Total | $255,968 | $262,729 | (3)% |

For the nine months ended February 28, 2018, net sales decreased $6.8 million to $256.0 million compared to the same period in the prior year.

- Consolidated net sales decreased from the prior year as a result of decreased net sales from Peripheral Vascular and Vascular Access. This decrease was partially offset by 4% year over year growth in our Oncology/Surgery Global Business Unit.

#### Peripheral Vascular

- Total Peripheral Vascular sales decreased $4.9 million primarily attributable to decreased sales volume of Venous and Angiographic products of $8.6 million. The decrease in our Venous product line of $6.1 million is due to reimbursement challenges. The decrease in our Angiographic product line of $2.5 million is related to the prior year volume from backorders related to a competitor recall. These decreases were offset by strong performance in our Fluid Management product line, which increased $2.8 million year over year. The increase in Fluid Management was attributed to the Fluid Management dedicated sales team being fully staffed and promoting new custom kits.
- U.S. Peripheral Vascular sales decreased $4.6 million and international Peripheral Vascular sales decreased $0.3 million, which was primarily due to decreased sales volume of Venous and Angiographic core products. This decreased sales volume was offset by an increase in volume in Fluid Management and Thrombus Management categories.

#### Vascular Access

- Total Vascular Access sales decreased $3.1 million primarily due to declines in our non-BioFlo businesses. Our BioFlo product lines, other than PICC sales, increased $2.2 million year over year, while BioFlo PICC sales decreased $2.2 million. BioFlo product lines now comprise 49% of our overall Vascular Access sales, compared to 47% a year ago.
- U.S. Vascular Access sales declined by 5% due to softness across the non-BioFlo portfolio offset by Midline and BioFlo Ports and BioFlo Dialysis which continue to gain traction in the marketplace.
- International Vascular Access sales decreased by $0.1 million.

#### Oncology/Surgery

- Total Oncology/Surgery sales increased $1.3 million year over year primarily due to the successful launch of our Solero product line, which generated $3.7 million of growth year over year.
- U.S. Oncology/Surgery declined by 3%, driven primarily by the timing of NanoKnife disposable sales of $0.7 million and market challenges in the Radiofrequency Ablation product line which decreased sales by $1.3 million. This was partially offset by increased Microwave capital and disposable sales of $1.3 million.
- International Oncology/Surgery sales increased $1.8 million year over year as a result of increased Microwave capital and disposable sales of $2.4 million and NanoKnife capital and disposable sales of $0.5 million. This was partially offset by decreased Radiofrequency Ablation sales of $1.3 million. The decrease in Radiofrequency Ablation was

primarily due to the discontinuation of this product line in Japan. In the prior year there was a $1.7 million sale to introduce Radiofrequency Ablation into the Japanese market.

### Gross Profit, Operating expenses, and Other income (expense)

|  | Nine months ended Feb 28, 2018 | Feb 28, 2017 | % Change |
| --- | ---: | ---: | ---: |
| Gross profit | $129.4 | $133.8 | (3)% |
| Gross profit % of sales | 50.6% | 50.9% |  |
| Research and development | $19.0 | $18.6 | 2% |
| % of sales | 7.4% | 7.1% |  |
| Selling and marketing | $56.4 | $58.3 | (3)% |
| % of sales | 22.0% | 22.2% |  |
| General and administrative | $23.3 | $23.1 | 1% |
| % of sales | 9.1% | 8.8% |  |

Gross profit - Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead, exclusive of intangible amortization.

Gross profit decreased by $4.4 million compared to the prior year. The decrease is attributable to the following:

- In second quarter of fiscal year 2018, the Company decided to discontinue selling our Radiofrequency Ablation product in Japan which resulted in a $1.7 million inventory provision. Volume softness, product mix and pricing headwinds of approximately $7.3 million were offset by the expiration of a royalty agreement of approximately $2.3 million and net productivity of approximately $2.1 million.

Research and development expenses - Research and development (“R&D”) expenses include internal and external costs to develop new products, enhance existing products, validate new and enhanced products, and manage clinical, regulatory and medical affairs.

R&D expense increased $0.4 million compared to the prior year. The increase is attributable to the following:

- Timing of project spend in the third quarter of fiscal year 2018 compared to prior year was up $0.4 million along with increased compensation and benefits associated with additional headcount of $0.1 million. This was partially offset by a decrease in recruiting expense of $0.2 million.
- R&D expense as a percentage of sales increased slightly year over year as a result of the higher R&D expense along with lower sales in the third quarter of fiscal year 2018.

Sales and marketing expenses - Sales and marketing (“S&M”) expenses consist primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities.

S&M expense decreased by $1.9 million compared to the prior year. The decrease is attributable to the following:

- Compensation and benefits decrease of approximately $2.6 million was primarily the result of decreased variable compensation of $2.2 million and open headcount of $0.4 million.
- Open headcount resulted in increased travel of $0.4 million and recruiting expense of $0.3 million.
- Lower consulting spend of $0.5 million was partially offset by increased samples expense related to the Solero launch of $0.2 million.

General and administrative expenses - General and administrative (“G&A”) expenses include executive management, finance, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities.

G&A expense increased by $0.2 million compared to the prior year. The increase is attributable to the following:

- Compensation and benefits increase of approximately $1.3 million was primarily the result of increased headcount year over year of $0.8 million which was partially offset by a decrease in bonus expense of $0.4 million. In addition, benefits expense increased $0.8 million due to significant favorability in the prior year.
- Higher professional fees of $0.3 million.
- These increases were partially offset by lower depreciation of $0.6 million, a decrease in bad debt expense of $0.2 million, a decrease in recruiting expense of $0.6 million and a decrease in travel expense of $0.1 million.

|  | Nine months ended Feb 28, 2018 | Feb 28, 2017 | $ Change |
| --- | ---: | ---: | ---: |
| Amortization of intangibles | $12.4 | $12.9 | $(0.5) |
| Change in fair value of contingent consideration | $0.2 | $(15.4) | $15.6 |
| Acquisition, restructuring and other items, net | $11.9 | $12.0 | $(0.1) |
| Other expense | $(2.0) | $(2.4) | $0.4 |

Amortization of intangibles - Represents the amount of amortization expense that was taken on intangibles assets held by the Company.

- The decrease of $0.5 million is primarily related to intangible assets that became fully amortized during the second quarter of the prior year.

Change in fair value of contingent consideration - Represents changes in contingent consideration driven by changes to estimated future payments on earn-out liabilities created through acquisitions and amortization of present value discounts on long-term contingent consideration.

- In the prior year, a gain of $13.4 million was taken on the AngioVac product as a result of decreases in future sales projections that eliminated any payments above the minimums and a gain of $3.1 million on the TiLo product as the milestone will not be achieved. The normal amortization of the present value discount on the contingent liabilities was approximately $0.1 million per quarter for the first two quarters of fiscal year 2018. In the third quarter the amortization is now less than $0.1 million as the final minimum payment was made on AngioVac in the second quarter of fiscal 2018.

Acquisition, restructuring and other items, net - Represents costs associated with mergers and acquisitions, restructuring expenses, legal costs that are related to litigation that is not in the ordinary course of business, legal settlements and other one-time items.

Acquisition, restructuring and other items, net decreased by $0.1 million compared to the prior year. The decrease is attributable to the following:

- In the prior year there was a $2.0 million write-off of Embomedics due to termination of the agreement and $3.6 million related to the decision to discontinue our investment in the TiLo product.
- There was $4.2 million of expense related to the plant consolidation that was announced in the third quarter of fiscal year 2017. The expense consisted mainly of severance of $1.5 million and costs to move the product lines including equipment transfer expenses, accelerated depreciation for assets that will not be transferred, product validation and other start up costs of $2.6 million. In the prior year, there was $0.2 million recorded for severance as of the end of the third quarter.
- Legal expenses, related to litigation that is outside of the normal course of business, of $7.3 million were recorded in the current year compared to $5.2 million in the prior year.

Other expenses - Other expenses include interest expense, foreign currency impacts, bank fees, and amortization of deferred financing costs.

- The decrease of $0.4 million was due to the prior year write-off of $0.7 million of deferred financing fees related to the original credit facility, offset partially by higher interest expense as a result of increased interest rates.

### Income Tax Provision (Benefit)

|  | Nine months ended Feb 28, 2018 | Feb 28, 2017 |
| --- | ---: | ---: |
| Income tax expense (benefit) | $(10.1) | $4.0 |
| Effective tax rate including discrete items | (244.0)% | 18.1% |

Our effective tax rate including discrete items for the three month periods ended February 28, 2018 and 2017 was (244.0)% and 18.1%, respectively.

The estimated annual effective tax rate, however, prior to discrete items was 4.9% in the third quarter of fiscal 2018, as compared to 42.9% for the same period in fiscal 2017. The Company’s effective tax rate differs from the U.S. statutory rate primarily due to the valuation allowance, foreign taxes and state taxes. The change from the prior quarter fiscal year 2017 is principally related to the enactment of the Tax Cuts and Jobs Act (“Tax Reform Act”) as it relates to amortization of goodwill for tax purposes which will no longer be treated as a permanent item in our tax provision.

On December 22, 2017, the President of the United States signed into law the Tax Reform Act. The legislation significantly changes U.S. tax law by, among other things, lowering corporate income tax rates, implementing a territorial tax system, expanding the tax base and imposing a tax deemed repatriated earnings of foreign subsidiaries. The Tax Reform Act permanently reduces the U.S. corporate federal income tax rate from a maximum of 35% to a flat 21% rate, effective January 1, 2018. The Company has recognized the impact of the Tax Reform Act in these unaudited consolidated financial statements and related disclosures. Staff Accounting Bulletin No. 118 (“SAB 118”) provides Companies with guidance on accounting for the impact of the Tax Reform Act. Specifically, SAB 118 provides for a measurement period, not to exceed one year, that begins on the date of enactment of December 22, 2017, and ends when the Company has obtained, prepared, and analyzed information needed to complete accounting requirements. In accordance with SAB 118, the Company recorded provisional amounts reflecting the impact of the Tax Reform Act in these unaudited consolidated financial statements and related disclosures.

As a result of the Tax Reform Act, in the third quarter of fiscal 2018, the Company has recognized a discrete tax benefit in the amount of $9.3 million due to the revaluation of the Company's indefinite lived deferred tax liability related to amortizable goodwill to reflect the lower statutory rate. Because the remaining U.S. deferred tax assets are offset by a full valuation allowance, the reduction in net deferred tax assets for the lower rate was fully offset by a corresponding reduction in valuation allowance resulting in no additional tax provision. The Tax Reform Act changed the NOL carryover rules and created a new limitation on their use. NOLs created in fiscal 2018 and beyond may be carried forwarded indefinitely but are limited to 80% of taxable income in any year. As a result of this change, the Company believes it is appropriate to offset some of its indefinite lived deferred tax liability against its deferred tax assets, and as a result, recognized an estimated $0.8 million discrete benefit in the third quarter of fiscal 2018. Additionally, this change impacts the Company's effective tax calculation on a go forward basis as the amortization of goodwill for tax purposes will no longer be treated as a permanent item in our tax provision.

The Tax Reform Act imposes a one-time transition tax on the deemed repatriation of post-1986 undistributed foreign subsidiaries’ earnings. Based on the information available as of December 31, 2017, the Company estimated undistributed foreign earnings of approximately $4.8 million. The taxable income arising from this deemed repatriation is expected to result in the utilization of net operating loss carryforwards and other tax credits, offset by changes in the valuation allowance, resulting in no net impact to tax expense. In accordance with SAB 118, the estimated income tax impact associated with the one-time transition tax of zero represents our best estimate based on interpretation of the U.S. legislation as we are still accumulating data to finalize the underlying calculation. In accordance with SAB 118, estimated income tax impact associated with the one-time transition tax is considered provisional and will be finalized prior to the end of the measurement period. The ultimate impact may differ from these provisional amounts, due to, among other things, additional analysis, changes in interpretations and assumptions the Company has made, additional regulatory guidance that may be issued, and actions the Company may take as a result of the Tax Reform Act.

A valuation allowance is established if it is more likely than not that all, or a portion of the deferred tax asset will not be realized. The Company has established that it is more likely than not that some, or all of their deferred tax assets will not be recognized in future years. Consequently, the Company continues to maintain a full U.S. valuation allowance on its net deferred tax assets. Management will continue to reevaluate the positive and negative evidence at each reporting period and if future results as projected in the U.S. and our tax planning strategies are favorable, the valuation allowance may be removed, which could have a favorable material impact on our results of operations in the period in which it is recorded.

### Liquidity and Capital Resources

Our cash and cash equivalents totaled $52.3 million as of February 28, 2018, compared with $47.5 million as of May 31, 2017. Marketable securities totaled $1.3 million as of February 28, 2018 and $1.2 million as of May 31, 2017, and consist of an auction rate security. As of February 28, 2018, total principal debt outstanding was $93.8 million and the fair value of contingent consideration payments was $3.2 million.

The table below summarizes our cash flows for the nine months ended February 28, 2018 and 2017:

*(in thousands)*

| Cash provided by (used in): | Nine Months Ended Feb 28, 2018 | Feb 28, 2017 |
| --- | ---: | ---: |
| Operating activities | $17,516 | $36,752 |
| Investing activities | (2,912) | (1,808) |
| Financing activities | (10,690) | (31,416) |
| Effect of exchange rate changes on cash and cash equivalents | 834 | (290) |
| Net change in cash and cash equivalents | $4,748 | $3,238 |

During the nine months ended February 28, 2018 and 2017, cash flows consisted of the following:

#### Cash provided by operating activities

- With regards to working capital, the Company continues to focus on optimizing days sales outstanding (DSO) which contributed to $2.9 million of working capital improvement. This working capital improvement was offset by increased inventory on hand of $1.9 million and $9.8 million of higher payments for accounts payable and accrued liabilities from May 31, 2017 through February 28, 2018.

#### Cash used in investing activities

- $1.6 million in fixed asset additions compared to $2.3 million in the prior year.
- In the third quarter of fiscal year 2018, we entered into a distribution and license agreement where we recorded the upfront license of $1.3 million as an intangible asset that will be amortized over 36 months.

#### Cash used in financing activities

- $3.8 million in repayments on long-term debt, consistent with the required amortization payment on the Term Loan, in the first nine months of fiscal year 2018 compared to $22.7 million in the first nine months of fiscal year 2017. The prior year payments include a $16.5 million payment to pay down the Revolving Facility in full.
- $2.6 million of proceeds from stock option and ESPP activity compared to $10.3 million in the first nine months of the prior year. The large decrease is related to the exercise of stock based awards from executive management turnover that took place in fiscal year 2017.
- $9.5 million payment on earn-out liabilities in the first nine months of fiscal year 2018 compared to $9.9 million in the first nine months of fiscal year 2017.
- $7.8 million from the repurchase of common shares in the first nine months of fiscal year 2017. There were no repurchases of common shares in the first nine months of fiscal year 2018.

On November 7, 2016, the Company entered into a Credit Agreement that provides for a $100.0 million senior secured term loan facility and a $150.0 million senior secured revolving credit facility, which includes up to a $20.0 million sublimit for letters of credit and a $5.0 million sublimit for swingline loans.

We believe that our current cash and investment balances, together with future cash generated from operations and our revolving credit facility capacity of up to $150.0 million as of February 28, 2018, will provide sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. If we seek to make significant acquisitions of other businesses or technologies in the future, we may require additional external financing.

## Market risk

As filed, 2,983 characters.

### Foreign Currency Exchange Rate Risk

We are exposed to market risk from changes in currency exchange rates, as well as interest rate fluctuations on our credit facility and investments that could impact our results of operations and financial position.

We transact sales in currencies other than the U.S. Dollar, particularly the Euro, British pound and Canadian dollar. Approximately 8% of our sales in the third quarter of fiscal 2018 were denominated in foreign currencies. We do not have expenses denominated in foreign currencies at the level of our sales and as a result, our profitability is exposed to currency fluctuations. When the U.S. Dollar strengthens, our sales and gross profit will be negatively impacted. In addition, we have assets and liabilities denominated in non-functional currencies which are remeasured at each reporting period, with the offset to changes presented as a component of Other (Expenses) Income. Significant non-functional balances include accounts receivable due from a sub-section of our international customers.

### Interest Rate Risk

On November 7, 2016, we entered into the Credit Agreement which provides for a $100 million senior secured Term Loan and a $150 million Revolving Facility. Interest on both the Term Loan and Revolving Facility is based on a base rate or Eurodollar rate plus an applicable margin which increases as our total leverage ratio increases, with the base rate and Eurodollar rate having ranges of 0.50% to 1.25% and 1.50% to 2.25% respectively. In the event of default, the interest rate may be increased by 2.0%. A 50 basis point (0.50%) increase or decrease in the interest rate would result approximately in a $2.0 million increase or decrease in interest expense over the life of the agreement.

### Concentration of Credit Risk

Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, our credit facility and trade accounts receivable.

The Company maintains cash and cash equivalents at various institutions and performs periodic evaluations of the relative credit standings of these financial institutions to ensure their credit worthiness. In addition, the Credit Agreement is structured across five above investment grade banks. The Company has the ability to draw equally amongst the five banks which limits the concentration of credit risk of one institution.

Concentration of credit risk with respect to trade accounts receivable is limited due to the large number of customers that purchase products from the Company. No single customer represents more than 10% of total sales. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. Although the Company does not currently foresee a significant credit risk associated with the outstanding accounts receivable, repayment is dependent upon the financial stability of our customers.

## Controls and procedures

As filed, 1,362 characters.

### Evaluation of disclosure controls and procedures

As of the end of the period covered by this report, our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

### Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting for the fiscal quarter ended February 28, 2018 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 684 characters.

In addition to information set forth in this report, you should carefully consider the factors discussed in “Part I, Item 1A. Risk Factors” of our annual report on Form 10-K for our fiscal year ended May 31, 2017 which set forth information relating to important risks and uncertainties that could materially adversely affect our business, financial condition or operating results. You should review and consider such Risk Factors in making any investment decision with respect to our securities. An investment in our securities continues to involve a high degree of risk. There have been no material changes to the risk factors previously disclosed in our annual report on Form 10-K.

Filed Apr 5, 2018.
Source: SEC EDGAR, the filing index for accession 0001275187-18-000007. Last ingested by Listed: Nov 4, 2026, 20:24 ET. No prices; not investment advice.
